Inhibition of lipoprotein lipase induced cholesterol ester accumulation in human hepatoma HepG2 cells.
It has been suggested previously that lipoprotein lipase may act as a ligand to enhance binding and uptake of lipoprotein particles. In the present study we have examined the capacity of bovine milk lipoprotein lipase to induce intracellular accumulation of triglyceride and cholesterol ester by VLDL (Sr 60-400) isolated from Type IV hypertriglyceridemic subject (HTg-VLDL) in HepG2 cells, independent of its lipolytic activity. We have also attempted to elucidate the cellular receptor mechanisms responsible for these effects. HTg-VLDL-mediated increases in intracellular triglyceride and cholesterol ester were dependent on the presence of an active lipase. Bovine milk lipoprotein lipase (LPL) increases triglyceride mass by 301% +/- 28% (P < 0.0005) and cholesterol ester mass by 176% +/- 12% (P < 0.0005). These HTg-VLDL-mediated increases in intracellular triglyceride and cholesterol ester did not occur when heat-inactivated lipase was used. Rhizopus lipase could replace LPL and cause equivalent increases in intracellular triglyceride and cholesterol ester (472% +/- 61%(P < 0.005) and 202% +/- 25% (P < 0.025) respectively vs. control). HTg-VLDL treated with LPL and reisolated also caused equivalent increases (274% +/- 18%(P < 0.01) and 177% +/- 12% (P < 0.005) for triglyceride and cholesterol ester). LDL also caused increases in intracellular cholesterol ester (189% +/- 20%(P < 0.005)), although three times more LDL cholesterol had to be added to achieve the same effect. These LDL-induced increases were effectively blocked by monoclonal antibodies directed against the B,E receptor binding domains of apo B (-97% +/- 13% (P < 0.0005) with anti-apo B 5E11 and -68% +/- 13% (P < 0.05) for anti-apo B B1B3) or by anti-B,E receptor antibodies (-77% +/- 7% (P < 0.01) antibody C7). These same antibodies had little effect on the HTg-VLDL+LPL-induced increases in cholesterol ester (+21%, +15% and -22% for 5E11, B1B3 and C7, respectively). Monoclonal anti-apo E antibodies also had no effect on LDL-mediated increases in intracellular cholesterol ester, but had a small and significant effect on VLDL-mediated increases in cholesterol ester. However, heparin, which interferes with cell surface proteoglycan interaction, was very effective at blocking HTg-VLDL-mediated increases in cholesterol ester in the presence of LPL (-86% +/- 8% P < 0.0005). Heparin was also effective in the presence of Rhizopus lipase (-79%) or lipolyzed re-isolated HTg-VLDL (-95%). These results suggest that lipoprotein lipase may enhance the uptake process beyond its role in lipolytic remodelling but does not appear to be an absolute requirement. In contrast, heparin had no effect on LDL-mediated cholesterol ester accumulation. Lactoferrin, which inhibits interaction with the low density lipoprotein receptor-related protein (LRP), was also very effective at inhibiting HTg-VLDL increases in intracellular cholesterol ester (-95% +/- 6%, P < 0.01). However, there was no effect of either heparin or lactoferrin on HTg-VLDL-mediated triglyceride accumulation. Thus cell surface heparin sulphate may facilitate intracellular lipid acquisition by providing a stabilizing bridge with the lipoproteins and enhance uptake through receptor-mediated processes such as LRP.
Cianflone
K
K
Robarts Research Institute, University of Western Ontario, London, Canada.
Avramoglu
R K
RK
Sawyez
C
C
Huff
M W
MW
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001057:Apolipoproteins E / Q000037:antagonists & inhibitors / Q000276:immunology; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001692:Biological Transport / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000378:metabolism / Q000473:pathology*; D002417:Cattle; D002788:Cholesterol Esters / Q000378:metabolism*; D004705:Endocytosis; D005260:Female; D005656:Fungal Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood; D007424:Intracellular Fluid / Q000378:metabolism; D007781:Lactoferrin / Q000494:pharmacology; D008066:Lipolysis; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008079:Lipoproteins, VLDL / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism / Q000473:pathology*; D008892:Milk / Q000201:enzymology; D008894:Milk Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011549:Pseudomonas / Q000201:enzymology; D012233:Rhizopus / Q000201:enzymology; D013045:Species Specificity; D014280:Triglycerides / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D001057:Apolipoproteins E; D001426:Bacterial Proteins; D002788:Cholesterol Esters; D005656:Fungal Proteins; D008079:Lipoproteins, VLDL; D008894:Milk Proteins; D014280:Triglycerides; D006493:Heparin; D008071:Lipoprotein Lipase; D007781:Lactoferrin